Guardant360 Response™ is the first blood-only test that enables doctors to view molecular response, or changes in the ctDNA levels, from a simple blood draw to get an early indication of patient response to immunotherapy or targeted therapy.

ctDNA changes may be detected earlier than radiographic changes among patients with initial stable disease.¹

For doctors, knowing early and confidently if a patient’s treatment is working is critical in deciding whether to continue, stop, or explore other options.

Easy to interpret report to assess your patient’s tumor response with a simple blood draw.

References :

1. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853.